NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.

TIMB, CRNT and PHI aim to ride the rising IoT and 5G demand, leveraging strong infrastructure, strategic expansion and long-term growth potential.

PDD's strategic investments create near-term volatility despite long-term potential. Hold current positions while new investors await clearer signals from Q1 results.

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the "Class Period"), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses.

American Century Focused Dynamic Growth ETF is an actively managed ETF focusing on 30–45 high-growth, mid-to-large-cap U.S. companies, that has consistently outperformed the Russell 1000 Growth benchmark. The fund's concentrated, differentiated portfolio and disciplined stock selection have generated strong returns post-Liberation Day, with strong risk-adjusted results. Given its track record, reasonable fees, and skilled management, I maintain a Buy rating for FDG as a compelling growth ETF option.

CAVA shines with soaring comps, strong traffic and rising estimates, while CMG faces inflation, soft sales and downward earnings revisions.

A soft freight market scenario, competitive pricing and declining liquidity weigh on JBHT's performance, undermining its prospects.

NEW YORK, May 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta's April 18, 2024 initial public offering (the “IPO”); or (2) between April 18, 2024 and February 26, 2025, inclusive (the “Class Period”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

CL gains from strong pricing, productivity moves, and an innovation strategy that supports continued momentum.

Paysafe sold its direct marketing payment processing business, with earnout payments potentially reaching $50 million a year after 2025. The business sale affected reported performance in the Merchant Solutions segment, while Digital Wallets performance proved more resilient. Constant currency growth from 2024 carried on into Q1 2025, with U.S. dollar reported growth also likely to resume in H2 2025.

Barrick Gold Corp. (TSX:ABX, NYSE:GOLD) said on Monday it expects a ruling on June 2 from the Bamako Commercial Tribunal on the Malian government's request to place its Loulo-Gounkoto gold mining complex under provisional administration. The request marks the latest flashpoint in a months-long standoff between the Canadian miner and Malian authorities.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In SoundHound AI To Contact Him Directly To Discuss Their Options

The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 28.8% in Roku (ROKU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 28.9% in Qifu Technology, Inc. (QFIN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 37% in Adeia (ADEA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 30.2% in Eastern Bankshares (EBC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in Consensus Cloud Solutions (CCSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.